- Home
- IOR vs SKYE Comparison
IOR vs SKYE Comparison
Compare IOR & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOR
- SKYE
- Stock Information
- Founded
- IOR 1984
- SKYE 2012
- Country
- IOR United States
- SKYE United States
- Employees
- IOR N/A
- SKYE N/A
- Industry
- IOR Real Estate Investment Trusts
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- IOR Real Estate
- SKYE Health Care
- Exchange
- IOR Nasdaq
- SKYE Nasdaq
- Market Cap
- IOR 75.2M
- SKYE 73.4M
- IPO Year
- IOR N/A
- SKYE N/A
- Fundamental
- Price
- IOR $18.95
- SKYE $3.81
- Analyst Decision
- IOR
- SKYE Buy
- Analyst Count
- IOR 0
- SKYE 6
- Target Price
- IOR N/A
- SKYE $16.60
- AVG Volume (30 Days)
- IOR 392.0
- SKYE 2.0M
- Earning Date
- IOR 08-07-2025
- SKYE 08-08-2025
- Dividend Yield
- IOR N/A
- SKYE N/A
- EPS Growth
- IOR N/A
- SKYE N/A
- EPS
- IOR 1.10
- SKYE N/A
- Revenue
- IOR N/A
- SKYE N/A
- Revenue This Year
- IOR N/A
- SKYE N/A
- Revenue Next Year
- IOR N/A
- SKYE N/A
- P/E Ratio
- IOR $17.24
- SKYE N/A
- Revenue Growth
- IOR N/A
- SKYE N/A
- 52 Week Low
- IOR $15.69
- SKYE $1.14
- 52 Week High
- IOR $19.30
- SKYE $8.26
- Technical
- Relative Strength Index (RSI)
- IOR 69.96
- SKYE 67.34
- Support Level
- IOR $17.95
- SKYE $3.41
- Resistance Level
- IOR $19.30
- SKYE $5.75
- Average True Range (ATR)
- IOR 0.06
- SKYE 0.54
- MACD
- IOR 0.05
- SKYE 0.14
- Stochastic Oscillator
- IOR 70.83
- SKYE 47.57
About IOR Income Opportunity Realty Investors Inc.
Income Opportunity Realty Investors Inc is a U.S.-based company that is an externally managed company that invests in mortgage notes receivables and real property. The business of the company is managed by Pillar Income Asset Management, Inc. The company's activities include locating, evaluating and recommending investment opportunities. Pillar also arranges its debt and equity financing with unaffiliated independent third party lenders and investors.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.